

# Clinical trial using bone marrow cells to treat heart failure

April 18 2016

---

Using a multi-cell therapy called Ixmyelocel, produced from a patient's (autologous) own bone marrow mononuclear cells (BM-MNCs), an ongoing clinical trial named "ixCELL-DCM" is being conducted in various locations in the U.S. for patients with heart failure. Because BM-MNC therapy requires a large number of cells, the cells are biologically enhanced to provide immune therapy to the myocardium for patients with heart failure.

"Heart failure continues to be a major cause of morbidity and mortality in the U.S.," said study co-author Dr. Timothy D. Henry of the Cedars-Sinai Heart Institute in Los Angeles. "Despite medical advances, mortality continues to approach 50 percent within five years."

The ixCELL-DCM trial is the first double-blind, placebo-controlled study of ixmyelocel-T administered by catheter injections to [patients](#) with [heart failure](#) (HF), according to the researchers. Ixmyelocel-T differs from other heart cell therapies because it contains "a complete range of BM-MNC types, but with selective expansion" of certain cell types to provide [immune therapy](#). The year-long study to assess efficacy, safety and tolerability is being conducted for a small number of qualified HF patients with ischemic dilated cardiomyopathy (IDCM) after earlier trials suggested that ixmyelocel-T might improve clinical, functional, symptomatic, and quality of life outcomes in patients with IDCM.

**More information:** Henry TD, Schaer GL, DeMaria A, Recker D, Remmers AE, Goodrich J, Patel AN. The iXCELL-DCM Trial:

Rationale and Design. *Cell Transplant*. Appeared or available on-line: March 22, 2016.

Provided by Cell Transplantation Center of Excellence for Aging and Brain Repair

Citation: Clinical trial using bone marrow cells to treat heart failure (2016, April 18) retrieved 24 April 2024 from <https://medicalxpress.com/news/2016-04-clinical-trial-bone-marrow-cells.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.